Tissue Regenix Group PLC Issue of Equity (6686R)
June 18 2018 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 6686R
Tissue Regenix Group PLC
18 June 2018
Tissue Regenix Group Plc
Issue of equity and total voting rights
Leeds, 18 June 2018 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Company"), the regenerative medical
devices company, announces that it has today issued and allotted
81,818 ordinary shares of 0.5p each in the Company, following an
exercise of options which were granted in respect of the 2017 DAB
awards.
The 81,818 new ordinary shares will rank pari passu with the
existing ordinary shares and application has been made for these
new ordinary shares to be admitted to trading on AIM. It is
expected that Admission will occur at 8:00a.m. on Thursday 21 June
2018.
Total Voting Rights
Following the issue of the 81,818 new ordinary shares, the
Company will have a total of 1,171,730,823 ordinary shares of 0.5p
each in issue. The above figure may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
For more Information:
Tissue Regenix Group plc
Caitlin Pearson Head of Communications Tel: 0330
430 3073
/ 07920272441
======================================== ================
Jefferies International Ltd Tel: 020
Simon Hardy / Chris Binks 7029 8000
======================================== ================
FTI Consulting Tel: 0203
Brett Pollard/ Mo Noonan / Rob Winder 727 1000
======================================== ================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEBDLLFVQFZBBF
(END) Dow Jones Newswires
June 18, 2018 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024